Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras homolog family member H (RhoH) is a small GTPase of the Ras superfamily, expressed specifically in hematopoietic cells where it functions as a negative regulator of cell growth and survival[1][3][7]. RhoH lacks intrinsic GTPase activity and remains constitutively active, acting as an antagonist of Rac signaling in hematopoietic lineages[3]. In T lymphocytes, it plays a critical adaptor role in T-cell receptor (TCR) signaling and is required for proper thymocyte development and immune function. Chromosomal translocations involving RHOH are associated with non-Hodgkin's lymphoma and its deregulation/mutation is implicated in leukemia, lymphoma, and immunodeficiency syndromes[1][2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras homolog family member H (RhoH).